Organization
Melanoma Institute Australia
11 clinical trials
32 abstracts
Clinical trial
A Multicentre, Open Label, Phase II Study to Determine the Response to Neoadjuvant Pembrolizumab and Lenvatinib Followed by Adjuvant Treatment With Pembrolizumab and Lenvatinib in Mucosal MelanomaStatus: Not yet recruiting, Estimated PCD: 2026-05-01
Abstract
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).Org: The University of Sydney, University of Pittsburgh Medical Center, Medical University of Vienna, Perlmutter Cancer Center at NYU Langone Health Medical Center, Elbe Klinikum Buxtehude,
Abstract
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario Virgen Macarena, Maria Skłodowska-Curie National Institute of Oncology Center, Poznan University of Medical Sciences and Greater Poland Cancer Center, UPMC Hillman Cancer Center,
Abstract
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.Org: Laura and Isaac Perlmutter Cancer Center, Sir Charles Gairdner Hospital, Washington University Oncology, Sarah Cannon Research Institute/Tennessee Oncology, One Clinical Research and Edith Cowan University,
Abstract
External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.Org: The University of Texas MD Anderson Cancer Center, The University of Sydney, Melanoma Institute Australia, Royal Prince Alfred Hospital, Sydney, NSW, Australia,
Abstract
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.Org: Melanoma Institute Australia, Mater and Royal North Shore Hospitals, Leiden University Medical Center, University Medical Center Utrecht, University Medical Center Groningen,
Abstract
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.Org: Netherlands Cancer Institute (NKI-AVL), The Netherlands Cancer Institute, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals,
Abstract
A randomised, controlled, multicentre trial of imiquimod versus radiotherapy for lentigo maligna.Org: Melanoma Institute Australia, The University of Sydney, Chris O'Brien Lifehouse, Icon Cancer Centre, Faculty of Medicine and Health, The University of Sydney,
Abstract
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,
Abstract
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: The primary analysis of an EORTC randomized phase II study (EBIN).Org: Gustave Roussy Cancer Campus, EORTC Headquarters, Université Clermont Auvergne, Dermato-Oncology and CIC AP-HP Hôpital Saint Louis, Université de Versailles-Saint Quentin en Yvelines,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study.Org: University Hospital (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany, University Hospital Zürich Skin Cancer Center, Zürich, Switzerland, Fondazione IRCCS - Istituto Nazionale dei Tumori (INT), Milano, Italy, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Woolloongabba, QLD, Australia, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy,
Abstract
Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048.Org: Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, University Hospital Zurich, Zürich, Switzerland, CEPCM, Dermatology and Skin Cancer Department, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France, Linear Clinical Research, Nedlands, Western Australia, Australia, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,
Abstract
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.Org: Department of Medical Oncology, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Center for Cancer Prevention and Early Detection, City of Hope, Phoenix, AZ, Eastern Health & Epworth Healthcare & Eastern Health Clinical School, Monash University, Melbourne, Australia,
Clinical trial
A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases.Status: Recruiting, Estimated PCD: 2024-08-01
Abstract
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).Org: Melanoma Institute Australia,
Abstract
Combined EORTC FDG-PET/CT and RECIST 1.1 response criteria and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.Org: A.C. Camargo Cancer Center, Melanoma Institute Australia,
Abstract
Use of early circulating tumour DNA dynamics in patients with stage III melanoma receiving neoadjuvant combination immunotherapy.Org: Macquarie University, Chris O'Brien Lifehouse, Melanoma Institute Australia, Netherlands Cancer Institute (NKI-AVL),
Abstract
Camrelizumab plus apatinib and temozolomide as first-line therapy for advanced acral melanoma: 2-year survival results from CAP 03.Org: Department of Melanoma and Sarcoma Oncology, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, Melanoma Institute Australia, Department of Genitourinary Oncology,
Abstract
Neoadjuvant pembrolizumab plus lenvatinib in patients with resectable stage III melanoma (NeoPele): Analysis of tumor microenvironment (TME) correlated to pathological response.Org: Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Charles Perkins Centre, The University of Sydney, The University of Sydney, Blacktown Hospital,
Clinical trial
A Phase II, Open Label, Single Arm Study of Neoadjuvant Pembrolizumab and Lenvatinib for Patients With Resectable Stage III MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-01-31
Clinical trial
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage II To IV Resectable Cutaneous Squamous Cell CarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Pilot Study to Evaluate Short Term Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinomas in Cosmetically Challenging LocationsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 2, Open Label, Single Arm, Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous MelanomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2017-09-04
Clinical trial
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-01-02
Clinical trial
A Phase 2, Open Label, Single Arm Clinical Trial of Neoadjuvant Nivolumab and Relatlimab in Stage I To III Resectable Merkel Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive MelanomaStatus: Active (not recruiting), Estimated PCD: 2017-05-04
Abstract
Revisiting the optimal neoadjuvant immunotherapy regimen in resectable stage III melanoma based on the interferon gamma signature: A pooled analysis.Org: Netherlands Cancer Institute, Melanoma Institute Australia, Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Netherlands Cancer Institute (NKI-AVL),
Abstract
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.Org: Melanoma Institute Australia, The Netherlands Cancer Institute, Amsterdam University Medical Centers, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The Christie NHS Foundation Trust,
Abstract
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).Org: Melanoma Institute Australia, The University of Sydney, Sydney, Australia, Wollstonecraft, NSW, Australia, Sydney, NSW, Australia,
Abstract
Neoadjuvant T-VEC + nivolumab combination therapy for resectable early metastatic (stage IIIB/C/D-IV M1a) melanoma with injectable disease: NIVEC trial.Org: Division of Surgical Oncology, Department of Surgery, The Ohio State University, Netherlands Cancer Institute, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, The Netherlands Cancer Institute,
Abstract
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in high-risk stage II cutaneous melanoma: NeoReNi II.Org: Melanoma Institute Australia, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, Chris O'Brien Lifehouse, The University of Sydney, The Mater Hospital Sydney,
Abstract
The impact of emotional distress on pathologic response and survival after neoadjuvant combination immune checkpoint blockade (ICB) in high-risk stage III melanoma.Org: Netherlands Cancer Institute, Division of Psychosocial Oncology and Epidemiology, Core Facility Molecular Pathology and Biobanking, Melanoma Institute Australia, The University of Sydney,
Abstract
FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma.Org: A.C. Camargo Cancer Center, São Paulo, Brazil, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil, Beneficencia Portuguesa, AC Camargo Cancer Center,
Abstract
Phase III study of adjuvant encorafenib plus binimetinib versus placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design.Org: Melanoma Institute Australia, University Hospital (UKSH), Campus Kiel, Department of Dermatology, Kiel, Germany, University of Perugia, Ospedale Santa Maria della Misericordia, European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, European Organization for Research and Treatment of Cancer (EORTC), Headquarters,
Abstract
Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.Org: Vanderbilt University School of Medicine, Massachusetts General Hospital, Melanoma Institute Australia, Laura and Isaac Perlmutter Cancer Center, NYU School of Medicine, Georgetown University Medical Center,
Abstract
Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma.Org: University Hospital Essen, University Hospital Zurich, Melanoma Institute Australia, University Hospital Heidelberg, Universitaetsklinikum Erlangen,
Abstract
Intralesional therapy, limb infusion/perfusion, and immune checkpoint inhibitors as first-line therapy in surgically unresectable melanoma in-transit metastases.Org: H. Lee Moffitt Cancer Center and Research Institute, Moffitt Cancer Center, University of North Carolina at Chapel Hill, Mayo Clinic, Netherlands Cancer Institute,
Abstract
Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy.Org: Melanoma Institute Australia, Netherlands Cancer Institute (NKI), Department of Dermatology, APHP St Louis, Alfred Health,
Abstract
Population-based validation of the Melanoma Institute Australia (MIA) and the Memorial Sloan-Kettering Cancer Center (MSKCC) predictive tool for sentinel node status in patients with melanoma.Org: University of Linköping, Linköping University Hospital, Sweden, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Institute of Clinical Sciences,
Abstract
CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Sir Charles Gairdner Hospital, Harry Perkins Institute for Medical Research, University of Western Australia & Linear Clinical Research, Melbourne, Australia,